Nabriva Therapeutics — Investor Presentation (April 2021)
30 slides from Nabriva Therapeutics's investor presentation, Apr 15, 2021
Slide 1: Uniquely Positioned to Deliver Innovative Treatments for Patients with Infectious Diseases
UNIQUELY POSITIONED TO DELIVER INNOVATIVE TREATMENTS FOR PATIENTS WITH INFECTIOUS DISEASES April 2021
Slide 2: Safe Harbor and Disclaimer
Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully commercialize XENLETA for the treatment of CABP, including the availability of and ease of
Slide 3: Nabriva Recent Corporate Highlights
Nabriva Recent Corporate Highlights Positive Momentum and Important Milestones in Light of COVID-19 Challenges 3 ✓ Strengthened Balance Sheet ✓ Prudent financial management ✓ Continued assessment of pipeline/ lifecycle management and business development opportunities ✓ Regulatory approvals in Europ
Slide 4: Looking to the Future: 2021 Key Objectives
Looking to the Future 2021 Key Objectives * CONTEPO is an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date. Resubmit Contepo™ NDA after FDA clarifies international pla
Slide 5: Nabriva Leadership Team
Nabriva Leadership Team Significant Commercial and Development Experience in Serious and Rare Diseases 5
Slide 6: XENLETA and SIVEXTRO Commercial Opportunity
XENLETA and SIVEXTRO COMMERCIAL OPPORTUNITY
Slide 7: XENLETA: A Promising Treatment Option for CABP
Complete Spectrum of Coverage of Main CABP Pathogens Monotherapy with appropriate spectrum for CABP aligned with principles of antimicrobial stewardship; Low risk of C. difficile infection Generally Well Tolerated Low rates of discontinuations due to adverse events in Phase 3 clinical trials New Cla
Slide 8: Pneumonia: A Leading Cause of Morbidity, Mortality and Healthcare Cost
Pneumonia: A Leading Cause of Morbidity, Mortality and Healthcare Cost Macrolide resistance in respiratory isolates ≥25% in all regions of the U.S. #3 Cause of hospital readmission6 ~5MM Cases Annually in US1 #5 Cause of total hospitalizations7 #1 Cause of infectious death5 Mortality rate ~$17B ~15%
Slide 9: Recognized Fluoroquinolone Safety Concerns
Recognized Fluoroquinolone Safety Concerns FDA web site: Fluoroquinolone antimicrobial drugs information. EMA website: https://www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review Communications Issued by FDA and EMA 2008 2011 2013 201
Slide 10: SIVEXTRO: Once Daily, Short Course Monotherapy for ABSSSI
SIVEXTRO: Once Daily, Short Course Monotherapy for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 10 For ABSSSI Adults and Adolescent Patients • Potent activity against a broad range of pathogens, including MRSA • Adverse reactions leading to discontinuation: 1.0% in clinical trials •On
Slide 11: SIVEXTRO: Nabriva Began Direct Distribution on April 12th
SIVEXTRO: Nabriva began direct distribution on April 12th Recording 100% of Net Sales Under Product Sales 11 Q4 2020 60 Reps Deployed • Prior to April 12th, all gross sales fell under Merck NDC • A portion of gross sales recorded as collaboration revenue by Nabriva Nabriva anticipates seeing the ret
Slide 12: XENLETA & SIVEXTRO: Synergies in the Community
XENLETA & SIVEXTRO: Synergies in the Community Primary Care Podiatrists & Dermatologists Urgent Care A: Symphony Health a PRA Health Sciences company, estimated treatment courses, TRXs for 12 months ending June 2017 B: IQVIA: Community Market data analysis, 2018; Medical Claims (Dx) and Longitudinal
Slide 13: Sales Force Deployment
Sales Force Deployment 60 Territory Footprint Expected to Efficiently Engage 7,800 Target Customers 13 Sales Force Profile: • ~10 years community sales experience • Prior antibiotic sales and Specialty Pharmacy pull- through expertise • Extensive experience selling in-person and optimizing virtual e
Slide 14: Significant Number of Nabriva Interactions with Targets
Significant Number of Nabriva Interactions with Targets 37,000 Total Sales Calls Since October 2020 Represents ~96% of potential top two decile SIVEXTRO prescribers and 98% of potential top decile XENLETA prescribers 14 0 2000 4000 6000 8000 10000 12000 Family Medicine Podiatry Dermatology Infectiou
Slide 15: Managed Care - XENLETA: Major Wins to Date
Managed Care - XENLETA: Major Wins to Date >248MM with XENLETA on Formulary and Further Expanding Coverage in 2021 15 92% of Total Commercial Lives have access to XENLETA >78% Unrestricted Payer/PBM Status Express Scripts PBM Unrestricted United Health Group Unrestricted Anthem, Inc. Covered (PA/ST)
Slide 16: Managed Care - SIVEXTRO: Major Wins to Date
Managed Care - SIVEXTRO: Major Wins to Date >269MM with SIVEXTRO® on Formulary 93% of Total Commercial Lives have access to SIVEXTRO® Covered (PA/ST) Unrestricted Source: MMIT Data 3/26/2021 ~60% Unrestricted Payer/PBM Status United Health Group Unrestricted CVS Unrestricted Department of Defense –
Slide 17: Further Exploration of XENLETA (lefamulin) for Cystic Fibrosis
Further Exploration of XENLETA (lefamulin) for Cystic Fibrosis
Slide 18: Unmet Need in Cystic Fibrosis Patients with Persistent MRSA Infections
Unmet Need in Cystic Fibrosis Patients with Persistent MRSA Infections MRSA Associated with Poorer Outcomes 18 No approved treatments for acute exacerbations or chronic treatment of S. aureus 1. Annual Data Report 2018 Cystic Fibrosis Foundation Patient Registry 2. Annual Data Report 2019 Cystic Fib
Slide 19: Oral Outpatient Utilization Rates for CF Patients with Chronic MRSA
Oral Outpatient Utilization Rates for CF Patients with Chronic MRSA during an Acute Pulmonary Exacerbation 19 Survey of 152 CF Centers on Outpatient Antibiotic Utilization for MRSA1 No MRSA Rx consensus 1. Zobell,JT, et al. Pediatr Pulmonol. 2015;50(6):552-9. 2. Suwantarat N, et al. Diag Micro and I
Slide 20: Potential for XENLETA to Treat CF Patients with S. Aureus
Potential for XENLETA to Treat CF Patients with S. Aureus Efficacy in CABP Oral and IV formulations Potent activity against S. aureus Activity in biofilms Low mutation frequency Lung penetration –ELF; Macrophage Anti-inflammatory activity Safety profile (no renal toxicity) Potential Peak Sales of $1
Slide 21: CONTEPO Commercial Opportunity
CONTEPO COMMERCIAL OPPORTUNITY
Slide 22: CONTEPO: A Potential Alternative to Pip/Taz and Carbapenems
In-Patients Prioritized Accounts CONTEPO: A Potential Alternative to Pip/Taz and Carbapenems Attractive Carbapenem-sparing Monotherapy for cUTI Patients at Risk for MDR Organisms (2) ▪ Large unmet need in the United States in treating patients with MDR gram-negative infections, with mortality increa
Slide 23: Approved for a Broad Range of Serious Infections
Approved for a broad range of serious infections including***: – Postoperative infections, concomitant nephrolithiasis, Hydronephrosis, tumours and prostatitis – orthopaedics and traumatology: postoperative bone infections (infected Osteosynthesis, endoprosthesis), osteomyelitis, purulent arthritis,
Slide 24: CONTEPO: Current Regulatory Status
• Type A meeting held with the FDA on October 30th to obtain information related to the Agency’s thinking on the conduct of foreign inspections • The FDA informed us that it has not yet determined how it will conduct international inspections during the COVID-19 pandemic • Next steps and specific ti
Slide 25: Focusing on Nabriva's Future
FOCUSING ON NABRIVA’S FUTURE
Slide 26: Financial Highlights
26 Q4 2020 Q3 2020 Financial Highlights Q1 2021 Q2 2021 Q2 2021 •Cash & short-term investments = $41.6MM as of December 31st •Net proceeds of $35MM from recent financing and proceeds from ATM extends cash runway into Q4 21 •Record 100% of SIVEXTRO net sales starting on April 12th •Continued prudent
Slide 27: Nabriva's Pipeline and Commercialized Products
Nabriva’s Pipeline and Commercialized Products *Nabriva Therapeutics in commercial partnership with Sunovion for Canada. Program Indications Discovery Pre- clinical Phase 1 Phase 2 Phase 3 NDA/ MAA Filing Approval Comments XENLETA lefamulin (IV/oral) CABP FDA approval – August 2019 EMA approval – Ju
Slide 28: 2021 Key Objectives
2021 Key Objectives Remain Nimble and Optimize Resources in Light of Ever Changing COVID Environment * CONTEPO is an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date.
Slide 29: Appendix
Appendix 29
Slide 30: References for Slide
References for Slide 8 MIC=minimum inhibitory concentration. *Data presented are from 2010 to September 2019. Dataset provided by JMI Labs and the SENTRY Antimicrobial Surveillance Program. sentry-mvp.jmilabs.com. Accessed October 5, 2019. 1. National Ambulatory Medical Care Survey (NAMCS) and Natio
Nabriva Therapeutics — Investor Presentation (April 2021) on 6ix